NCT00712283

Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers

A Single Center, Randomized, Double-blind, Placebo-controlled, Parallel Group Design Study to Investigate the Effect of 12,5 mg, 25 mg, 50 mg and 75 mg Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 64 (estimated)
• Sponsor: Merz Pharmaceuticals GmbH · Industry
• Sex: All
• Age: 21 Years – 50 Years
• Healthy volunteers: Accepted

Summary

Determination of the ability to drive and operate machines after single and multiple oral dose of Neramexane as compared to placebo

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Neramexane mesylate	tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days

Timeline

• Start date: 2008-07-01
• Primary completion: 2009-03-01
• Completion: 2009-06-01
• First posted: 2008-07-09
• Last updated: 2009-12-07

Locations

1 site across 1 country: Germany